PMID- 15339560
OWN - NLM
STAT- MEDLINE
DCOM- 20050207
LR  - 20190922
IS  - 1672-1977 (Print)
IS  - 1672-1977 (Linking)
VI  - 1
IP  - 3
DP  - 2003 Sep
TI  - [Prognostic analysis of advanced non small cell lung cancer treated by sequential 
      chemo-radiation therapy combined with traditional Chinese medicine: a report of 
      54 cases].
PG  - 195-8
AB  - OBJECTIVE: To evaluate the influence of fewer courses and prolonged intervals of 
      chemotherapy on survival rate of advanced non small cell lung cancer (NSCLC) 
      patients treated by sequential chemo-radiation therapy combined with traditional 
      Chinese medicine (TCM). METHODS: From Jan. 2000 to Dec. 2001, 54 untreated 
      advanced NSCLC patients (2 stage IIIa, 18 stage IIIb, 34 stage IV) were treated 
      by sequential chemo-radiation therapy combined with TCM. The courses of 
      chemotherapy were reduced and the intervals of chemotherapy were longer than that 
      of the standard regimen. The efficacy and survival rate were documented and the 
      prognostic factors were analyzed. RESULTS: Complete remission (CR) was observed 
      in 1 case and partial remission (PR) in 20 cases. The overall objective response 
      rate was 40.4%. Median survival was 15.3 months, 1-, 2- and 3-year survival rate 
      were 53.7%, 28.9% and 9.6% respectively. The median survival of stage III and IV 
      were 21.8 months and 12.5 months respectively. The 1-, 2-, and 3-year survival 
      rates of stage III were 65.0%, 49.5%, 24.7% and that of stage IV were 47.0%, 
      23.3%, 0%, respectively. The quality of life was improved in most of the 
      patients. Cox's proportional hazards regression showed that improved quality of 
      life and treatment of TCM were the significant prognostic factors of overall 
      survival. CONCLUSION: Chemotherapy and radiotherapy combined with TCM is 
      beneficial to extending the interval of chemotherapy, improving the quality of 
      life, and increasing the survival rate of advanced NSCLC patients.
FAU - Han, Ming-Quan
AU  - Han MQ
AD  - Department of Integrated Traditional Chinese and Western Medicine, Pulmonary 
      Disease Hospital of Shanghai, Shanghai 200433, China. doctor.han@163.com
FAU - Su, Jin-Mei
AU  - Su JM
FAU - Huang, Hai-Yin
AU  - Huang HY
FAU - Long, Wei-Hong
AU  - Long WH
FAU - Qin, Li-Ping
AU  - Qin LP
FAU - Qin, Ping
AU  - Qin P
FAU - Liu, Wei
AU  - Liu W
FAU - Sheng, Zhao-Ying
AU  - Sheng ZY
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhong Xi Yi Jie He Xue Bao
JT  - Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine
JID - 101199657
RN  - 0 (Drugs, Chinese Herbal)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/radiotherapy
MH  - Combined Modality Therapy
MH  - Drugs, Chinese Herbal/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/mortality/radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Quality of Life
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
EDAT- 2004/09/02 05:00
MHDA- 2005/02/08 09:00
CRDT- 2004/09/02 05:00
PHST- 2004/09/02 05:00 [pubmed]
PHST- 2005/02/08 09:00 [medline]
PHST- 2004/09/02 05:00 [entrez]
AID - 189 [pii]
AID - 10.3736/jcim20030315 [doi]
PST - ppublish
SO  - Zhong Xi Yi Jie He Xue Bao. 2003 Sep;1(3):195-8. doi: 10.3736/jcim20030315.